![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 45, 35215-35223, November 10, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,From the Section of Mass Spectrometry, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852
Received for publication, May 23, 2000, and in revised form, June 29, 2000
| |
ABSTRACT |
|---|
|
|
|---|
Enrichment of Neuro 2A cells with docosahexaenoic
acid (22:6n-3) decreased apoptotic cell death induced by serum
starvation as evidenced by the reduced DNA fragmentation and caspase-3
activity. The protective effect of 22:6n-3 became evident only after at least 24 h of enrichment before serum starvation and was
potentiated as a function of the enrichment period. During enrichment
22:6n-3 incorporated into phosphatidylserine (PS) steadily, resulting in a significant increase in the total PS content. Similar treatment with oleic acid (18:1n-9) neither altered PS content nor resulted in
protective effect. Hindering PS accumulation by enriching cells in a
serine-free medium diminished the protective effect of 22:6n-3. Membrane translocation of Raf-1 was significantly enhanced by 22:6n-3
enrichment in Neuro 2A cells. Consistently, in vitro
biomolecular interaction between PS/phosphatidylethanolamine
/phosphatidylcholine liposomes, and Raf-1 increased in a PS
concentration-dependent manner. Collectively, enrichment of
neuronal cells with 22:6n-3 increases the PS content and Raf-1
translocation, down-regulates caspase-3 activity, and prevents
apoptotic cell death. Both the antiapoptotic effect of 22:6n-3 and
Raf-1 translocation are sensitive to 22:6n-3 enrichment-induced PS
accumulation, strongly suggesting that the protective effect of 22:6n-3
may be mediated at least in part through the promoted accumulation of
PS in neuronal membranes.
Mammalian brain is rich in long chain polyunsaturated fatty acids.
Docosahexaenoic acid (22:6n-3), the major n-3 fatty acid found in
brain, is highly enriched in neuronal cells (1). Growing evidences
support the essential role of 22:6n-3 in neuronal function. In animal
models n-3 fatty acid deficiency caused memory deficit (2), learning
disability (3, 4), and visual acuity loss (5). In humans, various
neurological disease states have been shown to be associated with a
deficient 22:6n-3 status, implying the influence of this fatty acid in
neuronal function (6, 7). In the case of preterm infants with
underdeveloped brains, the inclusion of 22:6n-3 fatty acid in infant
formula has been shown to improve visual attention (8). More recently,
it has been shown that 22:6n-3 is required for the survival of rat
retinal photoreceptors (9) and exerts a protective effect on apoptosis of retinal photoreceptors during development (10).
Neuronal apoptosis normally occurs during the development and
maturation period (11-13). However, it has been shown that various neurodegenerative conditions are also associated with apoptotic neuronal cell death (14-16). Neuronal cell survival is critically dependent on the supply of trophic factors, which influences downstream signaling pathways (17). For example, in many cells
phosphatidylinositol 3-kinase-dependent Akt
serine/threonine kinase transduces a survival signal through
phosphorylating proapoptotic protein BAD, which in turn
associates with 14-3-3, preventing the interaction of BAD with Bcl-2
and Bcl-XL (18-20). Deprivation of trophic factors inhibits phosphatidylinositol 3-kinase/Akt and subsequently BAD phosphorylation, which enables binding of BAD to Bcl-XL,
resulting in mitochondrial damage. Subsequent release of cytochrome
c activates caspases, ultimately leading to apoptotic cell
death (21).
Growing evidence indicates that Raf-1 activation, which is known to be
essential for transducing signals of many growth factors, can play an
important role in the regulation of apoptotic processes (22-24).
Activation of Raf-1 kinase has been shown to prevent apoptosis in
hematopoietic cells (22). It has been also shown that inhibition of
Raf-1 in cells expressing BCR/ABL, which protects these cells from
apoptosis induced by growth factor deprivation, can induce apoptosis
(23). In addition, expression of constitutively active mitochondrial
Raf-1 has been shown to restore antiapoptotic potential of a
transformation-deficient BCR/ABL mutant (24). Recently, it has been
reported that activation of mitochondrial Raf-1 is involved in the
antiapoptotic effect of Akt (25). Although mechanisms of Raf-1
activation is complex and still remains controversial, translocation of
Raf-1 to the membrane and subsequent phosphorylation are considered to
be important steps for its activation (26-29). It has been shown that
Raf-1 kinase contains distinct binding domains for acidic
phospholipids, phosphatidylserine, and phosphatidic acid (30), and
therefore the membrane localization of Raf-1 may be dependent on the
concentration of these phospholipids.
Phosphatidylserine is the major acidic phospholipid in mammalian cell
membranes and is particularly enriched with 22:6n-3 fatty acid (1). We
have previously demonstrated that 22:6n-3, which is abundantly present
in neuronal cells, promotes the accumulation of phosphatidylserine in
cell membranes (31, 32). In the present study, we explored the
biological significance of 22:6n-3 by examining its effect on apoptotic
behavior upon trophic factor removal in relation to its capacity to
modulate phosphatidylserine accumulation. We found that enrichment of
neuronal cells with 22:6n-3 increased the accumulation of PS and the
membrane localization of Raf-1, down-regulated caspase-3 activity, and
prevented apoptotic cell death under serum-free conditions. Its
protective potential was sensitive to the extent of PS accumulation,
suggesting that the observed antiapoptotic effect of 22:6n-3 may be
mediated at least in part through the enhanced PS accumulation in
neuronal membranes.
Dulbecco's modified Eagle's medium
(DMEM),1 fetal bovine serum,
and other tissue culture reagents were obtained from Life Technologies, Inc. Monoclonal antibodies for Raf-1 and caspase-3 were purchased from
Transduction Laboratories (Lexington, KY), and horse radish peroxidase-conjugated secondary antibodies were from Amersham Pharmacia
Biotech. Apoptotic DNA ladder kit was purchased from Roche Molecular
Biochemicals. Hoechst dye #33258 (bisbenzimide trihydrochloride #33258)
was purchased from Sigma. Silica gel 60 plates were obtained from
Analtech (Newark, DE). Fatty acids were obtained from Nu-Check
(Elysian, MN). [1-14C]Docosahexaenoic acid (50 mCi/mmol)
and [3H]thymidine (15 Ci/mmol) were purchased from NEN
Life Science Products and Amersham Pharmacia Biotech, respectively.
Cell Culture Conditions and Fatty Acid Supplementation--
Rat
pheochromocytoma PC12 cells were obtained from American Type Cell
Culture (ATCC). Cells were maintained in RMPI medium supplemented with
10% heat-inactivated horse serum and 5% fetal bovine serum in a
37 °C incubator containing 5% CO2 water saturated atmosphere. Mouse neuroblastoma Neuro 2A cells (ATCC) were maintained in DMEM (Life Technologies, Inc.) with 5% fetal bovine serum in 75-cm2 Corning culture flasks under a humidified atmosphere
of 95% air and 5% CO2 at 37 °C. The medium was changed
twice weekly, and cells were subcultured when confluent. For DNA
fragmentation assay by sedimentation or Hoechst staining, cells were
plated on 6-well plates at a density of 5 × 104/cm2 and 2.5 × 104/cm2, respectively. For DNA or mRNA
isolation, cells were cultured in 10 ml of medium in 10-cm culture
dishes. For direct exposure of cells to fatty acids, fatty acids were
bound to fat-free bovine serum albumin and presented to cells in medium
containing 40 µM vitamin E during serum starvation. To
test the effect of fatty acid enrichment, Neuro 2A cells were
supplemented with fatty acids for 24 or 48 h and then subjected to
serum starvation. Fatty acid stock solutions in chloroform or methanol
were dried, bound to fetal bovine serum in the presence of 40 µM vitamin E, and diluted in DMEM under the argon
atmosphere so that final concentrations of fatty acids and fetal bovine
serum became 25 µM and 0.5%, respectively. Non-enriched
controls were treated similarly during the enrichment period, but fatty
acids were omitted.
DNA Fragmentation Assay--
The DNA fragmentation assay by
differential sedimentation was performed as reported earlier (33).
Nuclei of PC12 or Neuro 2A cells were labeled with 1 µCi of
[3H]thymidine for 24 h. To induce apoptosis, cells
were washed gently twice with serum-free medium to remove
unincorporated label and then incubated in the serum-free medium for
5-24 h. When cells were enriched with fatty acids before serum
starvation, [3H]thymidine was added 24 h before the
termination of enrichment. After serum starvation, cells were harvested
and centrifuged at 200 × g for 10 min at 4 °C. An
aliquot of the supernatant was then precipitated with 25%
trichloroacetic acid. This fraction (S) reflects the amount of
[3H]thymidine released during apoptosis induced by
serum deprivation. The remaining cells were solubilized in a lysis
buffer containing 0.2% Triton X-100 in 10 mM Tris/EDTA
(TTE). The intact DNA (B) and the fragmented DNA (T) were then
separated by centrifugation at 13,000 × g for 10 min
at 4 °C. The fragmented DNA was precipitated from the supernatant
with 25% trichloroacetic acid. The pellets were resuspended in 1% SDS
and subjected to liquid scintillation. The percent DNA fragmentation is
expressed as the sum of counts from (S + T)/(B + S + T) × 100.
Analysis of DNA Ladder Formation--
Total genomic DNA was
isolated from Neuro 2A cells by using an apoptotic DNA ladder assay kit
(Roche Molecular Biochemicals) according to the manufacturer's
protocol. Briefly, after 48 h of serum withdrawal as mentioned
above, the cells were harvested by trypsinization, suspended in 200 µl of PBS, and lysed with equal amount of lysis buffer and incubated
at 70 °C for 10 min. After adding 100 µl of isopropanol, lysates
were mixed, and the genomic DNA was sheared by passing a few times
through a 25-gage needle attached to a 1-ml disposable syringe.
The whole lysate was charged on glass filters and washed, and DNA was
isolated. The isolated DNA was precipitated in ethanol and extracted
with phenol/chloroform/isoamyl alcohol, air-dried, and suspended in Tris/EDTA buffer. Six to eight µg of total DNA was charged on 2% agarose gel (Bio-Rad) in loading buffer, electrophoresed in Tris-buffered EDTA buffer containing 1 µg/ml ethidium bromide at 75 volts, and photographed under UV illumination.
Hoechst Staining--
After 48 h of serum deprivation, the
medium was centrifuged gently at 100 × g to collect
detached cells, which were subsequently fixed in 250 µl of 3.7%
formaldehyde. The cells still attached to the plate were fixed directly
on the plate with 750 µl of 3.7% formaldehyde for 15 min. Cells were
combined and centrifuged, and then 100 µl of Hoechst dye (24 µg/ml)
dissolved in 50% glycerol/PBS was added. After incubating for
at least 10 min, cells were observed by fluorescence microscopy with a
365-nm filter.
Immunoblotting of Caspase-3--
Neuro 2A cells were washed
twice with cold PBS, and the pellet was suspended in 100 µl of lysis
buffer that contained 20% Triton X-100, 50 mM NaCl, 25 mM Tris/HCl, and 1 mM phenylmethylsulfonyl fluoride. The protein concentration was determined by BCA assay using
bicinchoninic acid reagent (34). Ten micrograms of protein were loaded
onto a 15% SDS-polyacrylamide gel and electrophoresed at a constant
current of 30 mA, then transferred from the gel to a polyvinylidene
difluoride membrane at 45 volts for 1 h. Procaspase-3 (32 kDa) and
the 17-kDa fragment were immunoblotted with anti-caspase-3 (Transduction Laboratories) and visualized by enhanced
chemoluminescence detection.
Caspase-3 Activity Measurement--
Caspase-3 activity was
measured using a colorimetric assay kit (Biomol, Plymouth Meeting, PA)
according to the manufacturer's protocol. Briefly, cell lysates were
centrifuged at 10,000 × g for 10 min at 4 °C, and
protein concentrations in the resulting supernatants were determined by
BCA assay. Aliquots were incubated with
acetyl-DEVD-p-nitroanilide for 2 h at 37 °C, and the
absorbance at 405 nm was measured spectrophotometrically.
Reverse Transcription-PCR Analysis of Raf-1 mRNA--
Total
RNA was isolated from Neuro 2A cells using TriZOL reagent (Life
Technologies, Inc.) according to the manufacturer's protocol and
quantified spectrophotometrically. One microgram of isolated RNA was
treated with DNase 1 and used for first-strand cDNA synthesis. The
treated RNA was incubated with 1 µl (0.5 µg) of
oligo(dT)12-18 primer for 10 min at 70 °C and
reverse-transcribed by using 1 µl (200 units of Moloney murine
leukemia virus reverse transcriptase) of Superscript II RT (Life
Technologies, Inc.) in 20 µl of reaction buffer containing 2 µl of
2 × PCR buffer, 25 mM MgCl2, 1 µl of 10 mM dNTP mix, and 2 µl of 0.1 M of
dithiothreitol. The mixture was placed in a Perkin-Elmer 2400 Gene Amp
PCR system set at 42 °C for a 50-min cycle followed by a 15-min
incubation at 70 °C and a 4 °C soak. After reaction, the prepared
cDNA was recovered from the mixture after RNA was digested by
incubating with 1 µl of RNase H (2 units) for 20 min at 37 °C. To
1-2 µl of template cDNA, 25 µl of PCR reaction buffer (PCR
master mix, Roche Molecular Biochemicals) was added along with 1 µl
(40 pmol) each of an upstream primer GTC CAG TAG CCC CAA CAA TC-3' (a
20-mer positioned at 202 -221) and a downstream primer 5'-GCG CAG AAC AGC CAC CTC AT-3' (a 20-mer positioned at 517-498) obtained from Lofstrand Lab, Ltd (Gaithersburg, MD). PCR was then performed using 35 cycles programmed as follows: initial denaturation for 2 min at
94 °C and 15 s at 94 °C, annealing for 30 s at
55 °C, and primer extension for 1 min at 72 °C. One microliter
(20 pmol) of each G3PDH primers (CLONTECH,
California, CA) was used as a control providing a 450-base pair band. A
band of 316 base pairs was visualized by illuminating under UV light
after 4 µl of the PCR product was charged on 2% agarose gel
containing 1 µg/ml ethidium bromide (Sigma) and electrophoresed for
1 h at 80 V.
Fatty acid Incorporation Time Course--
Neuro 2A cells were
seeded on 6-well plates at a density of 4 × 105/cm in
2 ml of DMEM containing 5% fetal bovine serum. On the next day, 0.5 µCi of [3H]22:6n-3 was added in 2 ml of DMEM containing
0.5% fetal bovine serum and 40 µM vitamin E. The final
concentration of the fatty acid was adjusted to 20 µM
with unlabeled fatty acids. After 5, 11, 24, and 48 h of
incubation, the medium was removed, and the cells were washed with
medium containing 0.2% bovine serum albumin twice. Cells were
collected in methanol containing 0.5% (w/v) 2,6-di-tert-butyl-p-cresol (BHT), and lipids were
extracted according to the method of Bligh and Dyer (35). The lipid
extracts were dried and reconstituted in chloroform, and aliquots were
taken for radioactivity counting. The rest of the extracts were mixed with 25 µmol each of standard phospholipids and loaded on the TLC
plates. Lipids were separated, and each lipid band was scraped and
subjected to liquid scintillation counting as described earlier (36).
Separately, cells were enriched with 20 µM nonlabeled 18:1n-9 or 22:6n-3, and lipids were extracted as described above. Phosphatidylserine molecular species were determined by electrospray liquid chromatography/mass spectrometry as described previously (31, 32, 37).
Preparation of Unilamellar Vesicles--
Liposomes of varying
concentrations of phosphatidylcholine (PC), phosphatidylethanolamine
(PE), and phosphatidylserine (PS) were prepared by the following
methods. Desired amounts of 18:0-22:6 PC, PE, and PS (Avanti Polar
Lipids, Alabaster, AL) in chloroform were mixed, then dried under
argon. Lipids were reconstituted in 2 ml of 75 µM
2,6-di-tert-butyl-p-cresol (BHT) in cyclohexane. Samples were frozen on dry ice and then lyophilized under vacuum until
only a lipid film remained. The samples were purged under argon before
removing to an argon box, whereupon the lipids were reconstituted with
an appropriate volume of 50 µM diethylenetriamine pentaacetic acid in PBS. Solutions were mixed with a Vortex until a
colloidal suspension formed and then passed through a 0.1-µm polycarbonate filter on a mini-extruder (Avanti Polar Lipids) 11 times
to make unilamellar vesicles.
Analysis of Raf-1 and Membrane Interaction--
Anti-Raf-1
antibody (Transduction Laboratories) was immobilized on a CM5 sensor
chip (Biacore, Upsala, Sweden) using Biacore X as directed by
manufacturer's instructions. Briefly, upon activating the chip with
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide
hydrochloride and N-hydroxysuccinimide, bovine serum
albumin-free anti-Raf was coupled to the sensor chip for a total of
approximately 5000 RUs bound. After the coupling was finished,
the chip surface was deactivated with ethanolamine/HCl, pH 8.5. The
wash buffer used throughout was PBS. Raf-1 was captured on the chip
using cell lysate from Neuro-2A cells (ATCC). The cell lysate was
collected in radioimmune precipitation buffer (1× PBS, 1%
Igepal, 0.5% sodium deoxycholate, 0.1% SDS) containing 100 µg/ml phenylmethylsulfonyl fluoride. One flow cell was kept as the
control cell, and no lysate was passed over this cell. The experimental
cell had 15-20 RUs of Raf-1 captured on the surface, allowing
liposome and Raf-1 interaction at approximately a 1:1.5 ratio. The
liposomes were injected into the flow cells, and the association with
and dissociation from Raf-1 was measured. Regeneration of the anti-Raf
surface was completed in a two-step process. First, 10 mM
acetate, pH 4.0, was injected into the cells, followed by an injection
of radioimmune precipitation buffer. After allowing the chip surface to
equilibrate with PBS, the chip was again ready for use. The recovered
protein was analyzed by SDS-polyacrylamide gel electrophoresis followed
by Western blotting using Raf-1 antibody to confirm the identity of the
captured protein.
Translocation of Raf-1 in Neuro 2 Cells--
After enrichment of
Neuro 2A cells with fatty acids for 48 h, Neuro-2A cells were
washed and grown overnight in serum-free DMEM at 37 °C. The next
day, experimental cells were stimulated with 250 ng of recombinant
human BDNF (Promega, Madison, WI) in 5 ml of serum-free DMEM for
5-30 min at 37 °C. Membrane and cytosolic fractions were separated
as described earlier (30), with slight modifications. Briefly, after
the incubation, cells were washed with ice-cold PBS buffer, collected
in 10 ml of Buffer A (10 mM Hepes, pH 7.4, 2 mM
EDTA, 1 mM Na3VO4, and 1 mM phenylmethylsulfonyl fluoride), pelleted, and lysed
by sonication in 40 µl of Buffer B (Buffer A plus 50 mM NaF, 10 µg/ml aprotinin, and 10 mg/ml leupeptin). Unbroken cells and nuclei were removed by centrifuging at 1000 × g for 5 min at 4 °C. The supernatant was further
centrifuged at 100,000 × g for 80 min at 4 °C. The
supernatant (cytosol fraction) was collected, and the membrane pellet
was solubilized by sonication in 80 µl of Buffer B containing 100 mM NaCl and 1% Triton X-100. The protein content was
measured by the BCA protein assay. The Raf-1 protein from cytosol and
membrane fractions was detected by SDS-polyacrylamide gel
electrophoresis and Western blotting.
Statistical Analysis--
Statistical analysis was performed
using the Student's t test or Bonfferoni/Dunn post
hoc analysis.
Direct Exposure of Neuronal Cells to 22:6n-3 Does Not Prevent DNA
Fragmentation Induced by Serum Starvation--
Incubation of PC-12 or
Neuro 2A cells under the serum-free conditions for 5 h induced
apoptotic cell death, as determined by genomic DNA fragmentation,
although Neuro 2A cells yielded much less fragmentation. Although
coincubation of cells with 20:4n-6 during the serum deprivation period
dose-dependently decreased the genomic DNA fragmentation
induced by serum starvation, 22:6n-3 (1-25 µM) was not
effective at all (Fig. 1). At a higher
concentration (50 µM), both fatty acids were toxic, and
DNA fragmentation increased significantly. The protective effect
appeared to be 20:4n-6-specific, since 12.5-25 µM
18:1n-9 did not have any significant effect as was the case with
22:6n-3.
Prolonged Enrichment with 22:6n-3 Reduces DNA Fragmentation by
Serum Starvation--
Since 22:6n-3 fatty acid exists mainly as
membrane phospholipids in neuronal cells, accumulation of this fatty
acid in membrane phospholipids may play an important role rather than
the free fatty acid itself. Therefore, Neuro 2A cells were first
enriched with 25 µM 22:6n-3, and the DNA fragmentation
induced by subsequent serum starvation was examined (Fig.
2). Unlike the case with direct exposure
of 22:6n-3 during 5-h serum starvation periods, Neuro 2A cells enriched
with 22:6n-3 for 24 h before serum starvation showed considerably
less DNA fragmentation in comparison with the cells enriched with
18:1n-9 or non-enriched controls. Enrichment of cells with 22:6n-3 for
48 h further protected cells, as was indicated by even less DNA
fragmentation. It was observed that the extent of protection or the
degree of DNA fragmentation induced by serum starvation differed
depending on the cell conditions or lot to lot variations in serum or
medium constituents. However, it was consistently observed that the
protective effect of 22:6n-3 was improved as the cells were enriched
for a longer period up to 48 h.
The Antiapoptotic Effect of 22:6n-3 Enrichment Is Maintained during
Prolonged Serum Starvation Period--
The cells enriched with 20:4n-6
also showed similarly less DNA fragmentation (Fig. 2); however, the
protective effect was sensitive to the duration of serum starvation as
shown in Fig. 3. The protective effect of
20:4n-6 observed during the 24-h serum-free conditions was abolished
when the cells were deprived of serum for 48 h. Only 22:6n-3
remained protective, with up to 48 h of serum starvation.
Similar results were obtained for the activity of caspase-3, a member
of cysteine protease family that has been shown to mediate apoptosis in
mammalian cells. Neuro 2A cells were first enriched with various fatty
acids for 48 h and then exposed to the serum-free medium for up to
48 h, during which period caspase-3 activity was followed. Fig.
4 shows the increase of caspase-3
activity as a function of the starvation period, with the exception of cells enriched with 22:6n-3. After 24 h of serum starvation, both 20:4n-6- and 22:6n-3-treated cells showed less caspase-3 activity in
comparison to non-enriched control or 18:1n-9-enriched cells. Upon
prolonged serum starvation, however, the protective effect of 20:4n-6
was no longer observed, and only 22:6n-3-treated cells maintained
caspase-3 activity at a level similar to 5% serum control.
Neuro 2A cells exhibited a characteristic DNA ladder pattern on an
agarose gel after serum starvation, confirming the occurrence of
apoptotic cell death. Neuro 2A cells required at least 48 h of
serum starvation for DNA ladder formation. Shown in Fig.
5 is the DNA ladder observed after the
cells were enriched with fatty acids for 48 h and subsequently
deprived of serum for 48 h. In agreement with the data shown in
Figs. 3 and 4, DNA ladder formation was significantly reduced after
enrichment with 22:6n-3, whereas other fatty acids such as 18:1n-9 or
20:4n-6 did not decrease the level of fragmentation. Consistent results
were also obtained using Hoechst staining as illustrated in Fig.
6. Serum-starved, non-enriched cells
contained condensed, bright, and fragmented nuclei, representing cells
undergoing apoptotic cell death. After enrichment with 22:6n-3 for
48 h before serum deprivation, the cells with fragmented nuclei
were much less visible, whereas the same treatment with 18:1n-9 showed
the results similar to the serum-starved, non-enriched control cells.
All these data strongly suggest that the anti-apoptotic effect of fatty
acid enrichment may be specific for 22:6n-3.
The Protective Effect of 22:6n-3 Correlated with the Extent of PS
Accumulation--
To relate biochemical mechanisms to the protective
effect of 22:6n-3 after a prolonged enrichment period, the
incorporation profile of this fatty acid was monitored in relation to
its protective effect. As shown in Fig.
7B,
[14C]22:6n-3, which was initially incorporated into
neutral lipids, was progressively remodeled to phospholipids,
especially PE and PS. When [14C]22:6n-3 was exposed to
cells for 5 h, radioactivity was distributed into neutral lipids
and phospholipids in the ratio of 41:59. Among these, triacylglycerol
and PC were the major lipid classes labeled, and their distribution was
22.0 ± 3.5% and 39.6 ± 1.3%, respectively. The free fatty
acid fraction contained 4.3 ± 0.4% of
[14C]22:6n-3. At 24 h, [14C]22:6n-3
was significantly enriched in PE (33.7 ± 1.2%) and PS (10.3 ± 0.3%) in comparison to the 5-h point, where PE and PS contained
only 13.0 ± 0.1 and 3.8 ± 1.1% of the 14C
label, respectively. Further enrichment for an additional 24 h
significantly increased the incorporation of [14C]22:6n-3
in PS (22.8 ± 4.0%), whereas 14C label in PE
appeared to be maintained (34.0 ± 3.3%) at the level of the 24-h
time point. After 48 h, more than 90% of the 14C
label was found in the phospholipid fraction. Phospholipid molecular species analysis by electrospray LC/MS revealed that the actual PS
content of 22:6n-3-treated cells also increased steadily during 48 h of the enrichment period (Fig. 7C), corroborating the
results obtained with radiolabeled 22:6n-3. The increase was mainly due to the 18:0,22:6-PS species, which changed from 1.0 ± 0.2 to
5.7 ± 0.2 pmol/µg of protein in 48 h. In contrast,
non-enriched control or 18:1n-9-treated cells did not show any
significant change in the PS content during the same enrichment period.
Consequently, 22:6n-3-enriched cells showed a significantly higher
total PS level (7.9 ± 0.3 pmol/µg of protein) in comparison
with that of non-enriched control or 18:1n-9-treated cells (3.4 ± 0.3 and 3.9 ± 0.1 pmol/µg of protein, respectively) at 48 h of enrichment. The protective effect of 22:6n-3 on DNA fragmentation
induced by serum starvation was potentiated as the cells were enriched for a longer period of time (Fig. 7A), and this increase
paralleled the PS accumulation during the time course of
enrichment.
In mammalian cells, PS is biosynthesized by the serine base exchange
reaction (38). Therefore, to modulate the PS accumulation, Neuro 2A
cells were enriched with fatty acids in a serine-free medium before
serum starvation, and caspase-3 activation was examined in relation to
PS accumulation (Fig. 8). Although
depleting serine from the media did not completely offset the PS
accumulation enhanced by 22:6n-3, increase in the PS content was
significantly lessened in comparison with the cells enriched in the
control medium (Fig. 8A). Concurrently, the protective
effect of 22:6n-3 on caspase-3 activation, as shown by enzymatic
activity (Fig. 8B) or Western blotting (Fig. 8C),
was either not observed or trivial in the cells kept in the serine-free
medium, supporting the notion that PS accumulation has a role in the
protective effect of 22:6n-3. Neither the caspase-3 activity nor the PS
content in 18:1n-9-treated or non-enriched control cells was
significantly affected by the serine-free conditions.
Fatty acid enrichment did not alter sphingolipid contents
significantly, although serine depletion decreased sphingolmyelin (SM)
levels. The SM contents were estimated to be 8.2 ± 1.7, 9.8 ± 0.8, or 8.6 ± 0.6 pmol/µg of protein under serine adequate
conditions and 4.8 ± 0.5, 3.8 ± 0.6 or 5.6 ± 0.5 pmol/µg of protein under serine-deprived conditions for control or
22:6n-3- or 18:1n-9-enriched cells, respectively. The ceramide
content could not be accurately quantified due to lack of a proper
internal standard. Nevertheless, it was possible to compare ceramide
contents in various cell culture samples based on the area ratios of
ceramide peaks calculated against the deuterium-labeled PC internal
standard peak in mass chromatograms. The area ratios thus obtained did
not alter significantly after various fatty acid treatments or serine
deprivation, indicating that ceramide levels were maintained at a
relatively constant level.
Enrichment of Neuro 2A Cells with 22:6n-3 Promotes the BDNF-induced
Raf-1 Translocation to Membranes--
Raf-1 kinase has been suggested
to be involved in cell survival (23-25). It has been shown that
membrane translocation is required for the activation of Raf-1 (26, 27)
and the regulatory domain interacting with PS plays an important role
in this process (30). Therefore, modulation of PS accumulation by
22:6n-3 may influence the translocation of Raf-1. Neuro 2A cells, first
enriched with 22:6n-3 for 48 h, were stimulated with BDNF for 30 min, and the membrane translocation of Raf-1 was examined in comparison
with unstimulated cells. As shown in Fig.
9A, Raf-1 translocated from cytosol to membrane fraction in response to BDNF. Cells enriched with
22:6n-3 showed significantly higher levels of membrane-associated Raf-1
in comparison to non-enriched control or 18:1n-9-enriched cells under
both basal and stimulated conditions. It was consistently observed that
the expression of total Raf-1 kinase was highest in 22:6n-3-treated
cells, as shown for protein and mRNA levels in Fig. 9B.
These results indicated that 22:6n-3 enrichment not only facilitated
the membrane translocation of Raf-1 but also up-regulated its
expression in Neuro 2A cells.
Interaction of Raf-1 with Lipid Membranes Is Dependent on the PS
Concentration--
As indicated above, the enrichment of Neuro 2A
cells significantly enhances PS accumulation as well as translocation
of Raf-1. To determine whether the enhanced PS concentration in cell
membranes played a role in the promoted translocation of Raf-1, the
interaction of this protein with liposomes with varying proportions of
PS was examined in vitro using biomolecular interaction
analysis. On a biosensor chip, Raf-1 protein was captured via
immobilized anti-Raf-1 antibody, and the binding of liposomes to the
captured Raf-1 was monitored by the changes in the surface plasmon
resonance signal resulting from the changes of the mass concentration
on the sensor chip surface due to the binding (39). The PS/PE/PC liposomes contained 50% PE and 0-50% PS and PC. As indicated in Fig.
10, the liposomes devoid of PS did not
interact with Raf-1, whereas the interaction was greater as the PS
proportion increased. All the phospholipids used contained 18:0,
22:6n-3 species, and the use of other fatty acid containing species
also produced similar results (data not shown).
In this study, we evaluated the role docosahexaenoic acid
(22:6n-3) in neuronal apoptosis induced by serum starvation. We demonstrated that 22:6n-3 enhances PS accumulation and protects neuronal cells from apoptotic cell death as a membrane component. The
observed positive correlation between PS accumulation and the
protective effect by 22:6n-3 strongly suggested that the antiapoptotic effect of 22:6n-3 enrichment may be mediated at least in part through
the promoted accumulation of PS in neuronal membranes. We also
demonstrated that positive modulation of PS accumulation by 22:6n-3
facilitates the translocation of Raf-1 to membranes.
When 22:6n-3 was simply added to medium during the serum starvation
period, the protective effect was not observed. In addition, the
absence of serine during the enrichment period diminished the
protective effect of 22:6n-3, suggesting that 22:6n-3, not as the free
fatty acid form but as a membrane component, particularly PS, may exert
its protective effect. The inhibition of caspase-3 activity, DNA
fragmentation by sedimentation method, DNA ladder formation, Hoechst
staining as well as caspase-3 cleavage to the 17-kDa active fragment
consistently indicated the anti-apoptotic effect of 22:6n-3 after
enrichment. In HL-60 cells, inhibition of sphingosine-induced apoptosis
by 22:6n-3 only after 24 h of enrichment has been reported
previously (40), similarly suggesting that 22:6n-3 as a membrane
component may be responsible for the observed effect. Along with the
modification of membrane phospholipid profile, the possibility of
altered gene transcription by 22:6n-3 during the enrichment period
cannot be excluded, since we observed the overexpression of Raf-1 in
22:6n-3-treated cells. In fact, a preliminary study identified several
genes whose expression is affected by 22:6n-3 enrichment (data not
shown). Nevertheless, the PS accumulation appears to be an important
factor in these processes.
It has been documented that the final steps of 22:6n-3 biosynthesis in
brain occurs in astroglia, where this fatty acid is readily released
(36, 41), suggesting that one of the supporting roles of astroglia may
include supplying 22:6n-3 fatty acid to neuronal cells for its
enrichment. The 22:6n-3 thus provided appears to accumulate in neuronal
membranes, since this fatty acid has been shown to be resistant to the
PLA2 action in neuronal cells (42, 43), in contrast to well
documented 20:4n-6 release in response to various neurotransmitters
(44). Among phospholipid classes in neuronal membranes, PS is
particularly enriched with 22:6n-3, which composes 35-40% of
the total fatty acid in PS (45). Concomitantly, the PS content has been
shown to be higher in neuronal cells in comparison to non-neuronal
cells (46, 47). All these data suggest that neuronal cells may
incorporate and retain 22:6n-3 in phospholipids to sustain particularly
high levels of PS in neuronal membranes. The present study also
indicated that 22:6n-3 is a positive modulator of PS accumulation in
Neuro 2A cells. Deprivation of serine from the media diminished the
effect of 22:6n-3 on PS accumulation, indicating that PS biosynthesis
is the major target for the enhanced PS accumulation.
The positive correlation between the antiapoptotic effect of 22:6n-3
enrichment and PS accumulation was evident since the protective effect
consistently responded to the PS content modulated by the enrichment
with various fatty acids, by varied enrichment period, and by depleting
the serine supply needed for the PS biosynthesis. In all cases, the PS
content paralleled the extent of the protective effect, strongly
suggesting that 22:6n-3 as a positive modulator of PS accumulation may
play a role in preventing neuronal apoptosis induced by serum
starvation. The electrospray LC/MS analysis of phospholipid molecular
species as described earlier (31, 37) indicated that Neuro 2A cells
enriched with 22:6n-3 in serine-free media did not produce
phosphatidylthreonine that has been previously observed in hippocampal
neurons (48).
Involvement of sphingolipids, particularly ceramides, in neuronal
apoptosis has been documented (49). The observed reduction of SM levels
in serine-free media (Fig. 8) corroborated the expected inhibition of
sphingolipid biosynthesis that requires serine (50). However, neither
fatty acid enrichment nor serine depletion affected ceramide levels
significantly, suggesting that there may be tight regulation in
maintaining basal levels of this signaling molecule involved in
apoptosis. There was little influence of 22:6n-3 enrichment on
sphingolipid levels regardless of the serine status, but serine was
required for the antiapoptotic effect of 22:6n-3 enrichment, strongly
suggesting sphingolipid involvement to be highly unlikely.
It has been indicated that 20:4n-6 released by the activation of
PLA2 modulates the activities of various signaling
molecules such as protein kinase C, G-proteins, and adenylate and
guanylate cyclases in response to stimulus (51). Initial protection of apoptosis, which was observed uniquely with 20:4n-6 fatty acid in
this study, may be due to the fatty acid itself since cyclooxygenase or
lipoxygenase inhibitors did not affect the protective effect of 20:4n-6
(data not shown). 20:4n-6 also increased the PS accumulation after
48 h of enrichment (5.9 ± 0.6 pmol/µg of protein) but was unable to effectively prevent apoptosis during long term serum starvation. The loss of the protective effect in 20:4n-6-enriched cells
after prolonged serum starvation suggests that other signaling pathways
may also be involved. Recently, it has been reported that
caspase-mediated cleavage of iPLA2 during apoptosis
augments spontaneous fatty acid release (52). It has been further
implied that cytosolic PLA2 and iPLA2
functionally cooperate so that Ca2+-dependent
cytosolic PLA2-mediated 20:4n-6 release can be promoted by
iPLA2 (52). Therefore, it is possible that the neuronal
membranes enriched with 20:4n-6 may be more susceptible to the
iPLA2 activity increased during serum starvation, so that
local free fatty acid levels may reach the toxic concentration range.
Alternatively, other death-signaling pathways sensitive to 20:4n-6 may
develop during the apoptotic process and may compromise the initial
protective effect.
Events underlying the process of neuronal cell proliferation,
differentiation, and apoptosis are becoming better established. Key
events in this process focus on signaling pathways derived from the
Ras/Raf-1/MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase)/mitogen-activated protein kinase cascade, as well as other pathways such as the activation of
phosphatidylinositol 3-kinase/Akt (53). It has been well documented
that PS is involved in various signaling pathways including protein
kinase C and Raf-1 kinase activation (30, 54, 55). Translocation of
Raf-1 kinase to cell membranes, an important step in growth factor
signaling, has been shown to be aided by Ras and membrane PS (30, 56). It has been also shown that Raf-1 interacts with PS through the PS
binding domain (30); however, the effect of PS concentration on their
interaction has not been elucidated. The configuration of Raf-1
employed in the present in vitro study may not be exactly compared with the free form due to its binding to anti-Raf-1 antibody in the biomolecular interaction analysis. Nevertheless, the observed PS
dependence in the interaction of Raf-1 and liposomes suggests that
antibody binding to Raf-1 may not significantly obscure its interaction
with PS. The in vitro demonstration of PS dependence (Fig.
10) corroborates the enhanced translocation of Raf-1 observed in
22:6n-3-enriched cells (Fig. 9), where PS concentration increased significantly (Fig. 8). Besides the role of Ras/Raf-1 activation in
proliferation, growing evidence indicates the importance of its
interaction with the phosphatidylinositol 3-kinase/Akt pathway for
ensuring cell survival in an either cooperative (26-28) or antagonistic manner (56, 57). To define where exactly in signaling pathways the enhanced translocation of Raf-1 by 22:6n-3 enrichment will participate to promote the survival signal under the serum-starved conditions, further studies will be necessary.
In summary, enrichment of neuronal cells with 22:6n-3 increases the PS
content and Raf-1 translocation, down-regulates caspase-3 activity, and
prevents apoptotic cell death. The correlation observed between the
degree of protective effect and the extent of PS accumulation as well
as the Raf-1 translocation enhanced by 22:6n-3 enrichment strongly
suggests that the protective effect of 22:6n-3 may be mediated at least
in part through the promoted accumulation of PS in neuronal membranes.
Therefore, we propose that 22:6n-3 as a positive modulator of the
membrane PS concentration may be an important biochemical mechanism
underlying the well recognized need for 22:6n-3 fatty acid in the
neuronal system.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (46K):
[in a new window]
Fig. 1.
Effect of fatty acids on DNA fragmentation
induced by serum starvation. PC-12 or Neuro 2A cells were
prelabeled with [3H]thymidine for 24 h and then
incubated in serum-free media for 5 h in the presence of fatty
acids at 0-50 µM. DNA fragmentation was evaluated by
sedimentation assay. The data presented are representative of three
experiments, each of which was performed using triplicate cultures.
Data are expressed as means ± S.D. Unpaired Student's
t test was performed in comparison to the control value. *,
p < 0.05; **, p < 0.01.

View larger version (55K):
[in a new window]
Fig. 2.
Effect of the fatty acid enrichment on DNA
fragmentation induced by serum starvation in Neuro 2A cells. Cells
were enriched with fatty acids at 25 µM for 24-48 h and
subsequently exposed to serum-free conditions. DNA fragmentation was
then evaluated by sedimentation assay. For labeling,
[3H]thymidine was added 24 h before the termination
of enrichment. The data presented are representative of three
experiments, each of which was performed using triplicate cultures.
Data are expressed as means ± S.D. Statistical significance was
tested using Bonfferoni/Dunn post hoc analysis. The values
designated with different letters are significantly different from each
other (p < 0.05).

View larger version (27K):
[in a new window]
Fig. 3.
Effect of the serum starvation period on the
DNA fragmentation in Neuro 2A cells. Cells were first enriched
with various fatty acids for 24 h in the presence of
[3H]thymidine and subsequently exposed to the serum-free
condition for 24 or 48 h. The data presented are representative of
two experiments, each of which was performed using triplicate cultures.
Data are expressed as % of control value at 24-h serum starvation
(means ± S.D.).

View larger version (21K):
[in a new window]
Fig. 4.
Effect of the serum starvation period on
caspase-3 activity in Neuro 2A cells. Cells were first enriched
with various fatty acids (25 µM) for 48 h and
subsequently exposed to the serum-free condition for up to 48 h.
Data are expressed as means ± S.D. obtained from triplicate
cultures.

View larger version (68K):
[in a new window]
Fig. 5.
Effect of fatty acid enrichment on DNA
fragmentation. Neuro 2A cells were enriched with various fatty
acids (25 µM) for 48 h and then subjected to serum
deprivation for 48 h. Isolated DNA was analyzed by agarose gel
electrophoresis. The representative data from at least three
experiments is presented.

View larger version (29K):
[in a new window]
Fig. 6.
Effect of fatty acid enrichment on DNA
fragmentation detected by Hoechst staining. Neuro 2A cells were
enriched with various fatty acids (25 µM) for 48 h
and then subjected to serum starvation for 48 h, followed by
staining with bisbenzimide trihydrochloride (Hoechst 33258). Fragmented
nuclei are indicated by arrows in the representative field
of each sample. DNA fragmentation was evaluated by counting condensed
or fragmented nuclei in each field where 500-800 cells were typically
scored. Statistical significance was tested using Bonfferoni/Dunn
post hoc analysis. The values designated with different
letters are significantly different from each other (p < 0.05).

View larger version (27K):
[in a new window]
Fig. 7.
Fatty acid enrichment time course in relation
to the protective effect of 22:6n-3. Neuro 2A cells were enriched
with 18:1n-9 or 22:6n-3 fatty acid (25 µM) for 5, 24, or
48 h, and the DNA fragmentation induced by subsequent 24-h serum
starvation was evaluated (A). In parallel, incorporation of
[14C]22:6n-3 (final concentration, 25 µM)
into various lipid classes was followed (B), and PS
accumulation was determined by LC/MS during the time course of
enrichment with 25 µM fatty acids (C). All
data points were obtained from triplicate samples. Two independent
experiments generated the similar results. In A, unpaired
Student's t test was performed in comparison to the control
value. **, p < 0.01. TG, triacylglycerol;
PI, phosphatidylinositol; PA, phosphatidic acid;
MG, monoacylglycerol; DG, diacylglycerol;
FFA, free fatty acid.

View larger version (27K):
[in a new window]
Fig. 8.
Effect of serine deprivation on the
accumulation of PS (A), caspase-3 activity
(B), and cleavage of caspase-3 to the 17KD active
fragment (C). Neuro-2A cells were enriched with
18:1n-9 or 22:6n-3 fatty acid (25 µM) for 48 h in
the serine-free or control media. The PS content was determined by
LC/MS at the end of the enrichment period in comparison to non-enriched
controls. Enriched and non-enriched control cells were subsequently
deprived of serum for 24 h, and caspase-3 activity and caspase-3
cleavage were evaluated after using acetyl-DEVD as a substrate and by
Western blotting, respectively. The data in A and
B were obtained from triplicate cultures, and the Western
blot data shown in C is representative of triplicate
samples. Two independent experiments generated similar results. In
B, unpaired Student's t test was performed in
comparison to the control value. **, p < 0.01

View larger version (23K):
[in a new window]
Fig. 9.
Effect of fatty acid enrichment on the
membrane translocation of Raf-1 (A) and Raf-1
expression (B). Neuro 2A cells were enriched with
25 µM 22:6n-3 or 18:1n-9 fatty acid for 48 h and
subjected to overnight serum starvation along with the non-enriched
control cells. After cells were stimulated with BDNF (50 ng/ml) for 30 min, membrane and cytosolic fractions were separated. Stimulated Raf-1
translocation was evaluated in comparison to basal translocation by
Western blotting (A). Separately, the levels of Raf-1
mRNA or protein in the whole cells were evaluated without
fractionation of membrane and cytosol by Western blotting and reverse
transcription-PCR (RT-PCR) (B). Three independent
experiments generated the similar data. G3PDH,
glyceraldehyde-3-phosphate dehydrogenase; bp, base
pairs.

View larger version (17K):
[in a new window]
Fig. 10.
Interaction of Raf-1 with PS evaluated
in vitro using biomolecular interaction analysis.
Unilamellar vesicles containing 18:0,22:6 species of PS/PE/PC in the
ratio ranging from 0/50/50 to 50/50/0 were interacted with Raf-1
captured on a gold surface via immobilized anti-Raf-1 antibody as
described under "Experimental Procedures." RU, relative
units.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Kun-Yang Kim, Karl Kevala, and Brian Nardini for their technical assistance in DNA fragmentation assay and lipid analysis.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Section of Mass
Spectrometry, LMBB/NIAAA, NIH, 12420 Parklawn Dr., Rockville, MD 20852. Tel.: 301-402-8746; Fax: 301-594-0035; E-mail: hykim@nih.gov.
Published, JBC Papers in Press, July 19, 2000, DOI 10.1074/jbc.M004446200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; 22:6n-3, docosahexaenoic acid; 20:4n-6, arachidonic acid; 18:1n-9, oleic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin; LC/MS, liquid chromatography/mass spectrometry; PLA2, phospholipase A2; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; BDNF, brain derived neurotrophic factor; iPLA2, Ca2+-independent phospholipase A2.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Salem, N., Jr. (1989) Omega-3 Fatty Acids: Molecular and Biochemical Aspects , pp. 109-228, Alan R. Liss, New York |
| 2. | Gamoh, S., Hashimoto, M., Sugioka, K., Shahdat Hossain, M., Hata, N., Misawa, Y., and Masumura, S. (1999) Neuroscience 93, 237-241 |
| 3. | Yoshida, S., Yasuda, A., Kawazato, H., Sakai, K., Shimada, T., Takeshita, M., Yuasa, S., Kobayashi, T., Watanabe, S., and Okuyama, H. (1997) J. Neurochem. 68, 1261-1268 |
| 4. | Carrie, I., Clement, M., De Javel, D., Frances, H., and Bourre, J. M. (1999) Neurosci. Lett. 266, 69-72 |
| 5. | Neuringe, M. (2000) Am. J. Clin. Nutr. 71 (suppl.), 256-267 |
| 6. | Hoffman, D. R., and Birch, D. G. (1998) World Rev. Nutr. Diet. 83, 52-60 |
| 7. | Martinez, M. (1992) Brain Res. 583, 171-182 |
| 8. | Birch, E. E., Hoffman, D. R., Uauy, R., Birch, D. G., and Prestidge, C. (1998) Pediatr. Res. 44, 201-209 |
| 9. | Rotstein, N. P., Aveldano, M. I., Barrantes, F. J., Roccamo, A. M., and Politi, L. E. (1997) J. Neurochem. 69, 504-513 |
| 10. | Rotstein, N. P., Aveldano, M. I., Barrantes, F. J., and Politi, L. E. (1996) J. Neurochem. 66, 1851-1859 |
| 11. | Sastry, P. S., and Rao, K. S. (2000) J. Neurochem. 74, 1-20 |
| 12. | Homma, S., Yaginuma, H., and Oppenheim, R. W. (1994) J. Comp. Neurol. 345, 377-395 |
| 13. | Oppenheim, R. W., Schwartz, L. M., and Shatz, C. J. (1992) J. Neurobiol. 23, 1111-1351 |
| 14. | Thompson, C. G. (1995) Science 267, 1456-1460 |
| 15. | Portera-Cailliau, C., Hedreen, J. C., Price, D. L., and Koliatsos, V. E. (1995) J. Neurosci. 15, 3775-3787 |
| 16. | Yamatsuji, T., Okamoto, T., Komatsuzaki, K., Komatsuzaki, K., Takeda, S., Fukumoto, H., Iwatsubo, T., Suzuki, N., Asami-Odaka, A., Ireland, S., Kinane, T. B., Giambarella, U., and Nishimoto, I. (1996) Science 272, 1349-1352 |
| 17. | Barde, Y. A. (1989) Neuron 2, 1525-1534 |
| 18. | Zha, J., Harda, H., Yang, E., Jockel, J., and Korsmeyer, S. J. (1996) Cell 87, 619-628 |
| 19. | Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241 |
| 20. | Dudek, H., Datta, S. R., Franke, T., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D., and Greenberg, M. E. (1997) Science 275, 661-665 |
| 21. | Green, D., and Reed, J. C. (1998) Science 281, 1309-1312 |
| 22. | Hoyle, P. E., Moye, P. W., Steelman, L. S., Blalock, W. L., Franklin, R. A., Pearce, M., Cherwinski, H., Bosch, E., McMahon, M., and McCubrey, J. A. (2000) Leukemia (Baltimore) 14, 642-656 |
| 23. | Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C., and Sawyers, C. L. (2000) Mol. Cell. Biol. 20, 1179-1186 |
| 24. | Salomoni, P., Wasik, M. A., Riedel, R. F., Reiss, K., Choi, J. K., Skorski, T., and Calabretta, B. (1998) J. Exp. Med. 187, 1995-2007 |
| 25. | Majewski, M., Nieborowska-Skorska, M., Salomoni, P., Slupianek, A., Reiss, K., Trotta, R., Calabretta, B., and Skorski, T. (1999) Cancer Res. 59, 2815-2819 |
| 26. | Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Science 264, 1463-1467; Correction (1994) Science 266, 1792-1793 |
| 27. | Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414 |
| 28. | King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M. S. (1998) Nature 396, 180-183 |
| 29. | Morrison, D. K., and Cutler, R. E. (1997) Curr. Opin. Cell Biol. 9, 174-179 |
| 30. | Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L., and Bell, R. M. (1996) J. Biol. Chem. 271, 8472-8480 |
| 31. | Garcia, M., C., Ward, G., Ma, Y. C., Salem, N., Jr., and Kim, H. Y. (1998) J. Neurochem. 70, 24-30 |
| 32. | Kim, H. Y., and Hamilton, J. (2000) Lipids 35, 187-195 |
| 33. | Duke, R. C., and Cohen, J. J. (1992) Current Protocols in Immunology, Suppl. 3 , pp. 3.17.1-3.17.16, Green/Wiley, New York |
| 34. | Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H, Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85 |
| 35. | Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911-917 |
| 36. | Garcia, M. C., and Kim, H. Y. (1997) Brain Res. 768, 43-48 |
| 37. | Kim, H. Y., Wang, T. C., and Ma, Y. C. (1994) Anal. Chem. 6, 3977-3982 |
| 38. | Kanfer, J. N. (1980) Can. J. Biochem. 58, 1370-1380 |
| 39. | Brigham-Burke, M., Edwards, J. R., and O'Shannessy, D. J. (1992) Anal. Biochem. 205, 125-131 |
| 40. | Kishida, E., Yano, M., Kasahara, M., and Masuzawa, Y. (1998) Biochim. Biophys. Acta 1391, 401-408 |
| 41. | Moore, S. A., Yoder, E., Murphy, S., Dutton, G. R., and Spector, A. A. (1991) J. Neurochem. 56, 518-524 |
| 42. | Kim, H. Y., Edsall, L., Garcia, M., and Zhang, H. (1999) Adv. Exp. Med. Biol. 447, 75-85 |
| 43. | Kim, H. Y., and Edsall, L. (1999) Lipids 34 (suppl.), 249-250 |
| 44. | Dumuis, A., Sebben, M., Haynes, L., Pin, J. P., and Bockaert, J. (1988) Nature 336, 68-70 |
| 45. | Hitzemann, R. (1981) Neurochem. Res. 6, 935-946 |
| 46. | Hamilton, J., Greiner, R., Salem, N., Jr., and Kim, H. Y. (2000) Lipids 35, 863-869 |
| 47. | White, D. A. (1973) Form and Function of Phospholipids , pp. 441-482, Elsevier Science Publishers B.V., Amsterdam |
| 48. | Mitoma, J., Kasama, T., Furuya, S., and Hirabayashi, Y. (1998) J. Biol. Chem. 273, 19363-19366 |
| 49. | Goswami, R., and Dawson, G. (2000) J. Neurosci. Res. 60, 141-149 |
| 50. | Merrill, A. H., Jr., and Jones, D. D. (1990) Biochim. Biophys. Acta 1044, 1-12 |
| 51. | Graber, R., Sumida, C., and Nunez, E. A. (1994) J. Lipid Med. Cell Signal. 9, 91-116 |
| 52. | Atsumi, G., Murakami, M., Kojima, K., Hadano, A., Tajima, M., and Kudo, I. (2000) J. Biol. Chem. 275, 18248-18258 |
| 53. | Kaplan, D. R. (1998) Prog. Brain Res. 117, 35-46 |
| 54. | Mosior, M., and Newton, A. C. (1998) Biochemistry 37, 17271-17279 |
| 55. | Winkler, D. G., Cutler, R. E., Jr., Drugan, J. K., Campbell, S., Morrison, D. K., and Cooper, J. A. (1998) J. Biol. Chem. 273, 21578-21584 |
| 56. | Zimmermann, S., and Moelling, K. (1999) Science 286, 1741-1744 |
| 57. | Rommel, C., Clarke, B. A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., and Glass, D. J. (1999) Science 286, 1738-1741 |
This article has been cited by other articles:
![]() |
J. E. Vance Thematic Review Series: Glycerolipids. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids J. Lipid Res., July 1, 2008; 49(7): 1377 - 1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cherubini, C. Andres-Lacueva, A. Martin, F. Lauretani, A. D. Iorio, B. Bartali, A. Corsi, S. Bandinelli, M. P. Mattson, and L. Ferrucci Low Plasma N-3 Fatty Acids and Dementia in Older Persons: The InCHIANTI Study J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2007; 62(10): 1120 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Kim Novel Metabolism of Docosahexaenoic Acid in Neural Cells J. Biol. Chem., June 29, 2007; 282(26): 18661 - 18665. [Full Text] [PDF] |
||||
![]() |
I. Kan, E. Melamed, D. Offen, and P. Green Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation J. Lipid Res., March 1, 2007; 48(3): 513 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
|